English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Capecitabine is an orally active prodrug of 5-fluorouracil with improved safety and efficacy that is extensively used as an antineoplastic agent. It is converted to 5-Fluorouracil in the liver and tumor tissues.  In vitro  assays did not reveal any significant potential for interaction between capecitabine and its metabolites with warfarin. However, several reports provided clinical evidence of such interaction resulting in an elevated international normalized ratio (INR) and bleeding. Here, we report another case of capecitabine and warfarin concurrent administration that resulted in sub- or supra- therapeutic INR without any bleeding episode or venous-thromboembolic event through the follow-up period. Moreover, a review of available management options is also presented in this paper.

Capecitabine and Warfarin Interaction: A Case Report With Review of Literature and Management Options